Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Natrecor NCD

Executive Summary

Medicare contractors may opt to cover J&J/Scios' Natrecor for some off-label uses despite a March 2 CMS national coverage decision against using nesiritide for chronic heart failure. The decision "does not change contractor discretion to cover other off-label uses of nesiritide" or affect coverage for the labeled indication of acutely decompensated heart failure, CMS said. The agency had expressed concern about the drug's potential for increased mortality rates and renal dysfunction. The NCD review found inconsistent data on use of Natrecor for chronic heart failure (1"The Pink Sheet" Dec. 12, 2005, p. 12)...

You may also be interested in...

Medicare Proposes To Cover J&J’s Natrecor For Labeled Indication Only

The Centers for Medicare & Medicaid Services is proposing to restrict Medicare coverage of Johnson & Johnson/Scios' Natrecor to its labeled indication for acutely decompensated heart failure, rather than provide wider coverage for the drug under a "coverage with evidence development" program

Celltrion Eyes M&A, Global Expansion And Novel Drugs As Founder Returns

Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.

Stage Set For Generics To Triumph With Skinny-Label Reversal

With the US solicitor general offering support for Teva over GSK in long-running litigation over skinny-label carve-outs of generic indications, the stage could be set for a major reversal at the Supreme Court that would favor the generics industry.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts